Stay updated on Pembrolizumab for Pediatric Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Pediatric Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Pembrolizumab for Pediatric Hodgkin Lymphoma Clinical Trial page
- CheckyesterdayChange DetectedThe footer revision number changes from v3.7.0 to v3.7.1, while the page remains a 403 Forbidden error page.SummaryDifference0.2%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe page now renders a 403 Forbidden error with a Home link, replacing the prior study record content. Content referencing Merck-related information and trial details has been removed in this view, resulting in an access-denied presentation rather than the full study record.SummaryDifference20%

- Check22 days agoChange DetectedEnd point definitions for EFS and OS were updated to anchor timing to the first dose and specify progression assessment methods; serum TARC biomarker endpoints were removed.SummaryDifference0.4%

- Check36 days agoChange DetectedThe revision label has advanced from v3.6.5 to v3.6.6, indicating a newly published update to the page; this update denotes versioning rather than substantive changes to study details.SummaryDifference0.0%

- Check43 days agoChange DetectedTwo NIH grant entries for 2017 and 2023 were added to the study record, indicating additional U.S. NIH funding support for this trial. This updates the funding context for readers reviewing the study's support sources.SummaryDifference0.1%

- Check57 days agoChange DetectedThe page revision version was updated from v3.6.4 to v3.6.5, signaling a small update to the page's content or metadata.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab for Pediatric Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Pediatric Hodgkin Lymphoma Clinical Trial page.